These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 10194427)

  • 21. Feasibility and kinetics of CD34
    Takhar H; Mislang AR; Singhal N; Brown MP
    Asia Pac J Clin Oncol; 2017 Feb; 13(1):79-86. PubMed ID: 27649817
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictive factors for peripheral-blood progenitor-cell collections using a single large-volume leukapheresis after cyclophosphamide and granulocyte-macrophage colony-stimulating factor mobilization.
    Passos-Coelho JL; Braine HG; Davis JM; Huelskamp AM; Schepers KG; Ohly K; Clarke B; Wright SK; Noga SJ; Davidson NE
    J Clin Oncol; 1995 Mar; 13(3):705-14. PubMed ID: 7533827
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase III randomized study comparing 5 or 10 microg per kg per day of filgrastim for mobilization of peripheral blood progenitor cells with chemotherapy, followed by intensification and autologous transplantation in patients with nonmyeloid malignancies.
    André M; Baudoux E; Bron D; Canon JL; D'Hondt V; Fassotte MF; D'Hondt L; Fillet G; Humblet Y; Jerusalem G; Vermeulen P; Symann M; Beguin Y
    Transfusion; 2003 Jan; 43(1):50-7. PubMed ID: 12519430
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhanced levels and enhanced clonogenic capacity of blood progenitor cells following administration of stem cell factor plus granulocyte colony-stimulating factor to humans.
    Begley CG; Basser R; Mansfield R; Thomson B; Parker WR; Layton J; To B; Cebon J; Sheridan WP; Fox RM; Green MD
    Blood; 1997 Nov; 90(9):3378-89. PubMed ID: 9345020
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biology and clinical potential of stem-cell factor.
    Glaspy J; Davis MW; Parker WR; Foote M; McNiece I
    Cancer Chemother Pharmacol; 1996; 38 Suppl():S53-7. PubMed ID: 8765418
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transplantation with low-density autologous PBSC prepared with BDS60 for women with Stage II, III and IV breast cancer.
    Laport GG; Valone FH; Zimmerman TM; Grinblatt DL; Van Vlasselaer P; Still BJ; Williams SF
    Cytotherapy; 2000; 2(3):179-85. PubMed ID: 12042040
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sequential analysis of CD34+ and CD34- cell subsets in peripheral blood and leukapheresis products from breast cancer patients mobilized with SCF plus G-CSF and cyclophosphamide.
    Menéndez P; Prósper F; Bueno C; Arbona C; San Miguel JF; García-Conde J; Solá C; Hornedo J; Cortés-Funes H; Orfao A
    Leukemia; 2001 Mar; 15(3):430-9. PubMed ID: 11237067
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors.
    Anderlini P; Donato M; Lauppe MJ; Huh YO; Martin TG; Chan KW; Champlin RE; Körbling M
    Br J Haematol; 2000 Jun; 109(4):770-2. PubMed ID: 10929027
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The comparison of Filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: a single center experience from Turkey.
    Sivgin S; Karakus E; Kaynar L; Kurnaz F; Pala C; Keklik M; Zararsiz G; Solmaz M; Eser B; Cetin M; Unal A
    Transfus Apher Sci; 2013 Jun; 48(3):315-20. PubMed ID: 23611684
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mobilization of peripheral blood progenitor cells (PBPC) through a combination of chemotherapy and G-CSF in breast cancer patients and a possibility of unprocessed whole blood collection.
    Vanásek J; Filip S; Medková V; Bláha M; Mericka P; Volenec K
    Bone Marrow Transplant; 1998 Jan; 21(2):123-6. PubMed ID: 9489627
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF.
    Koç ON; Gerson SL; Cooper BW; Laughlin M; Meyerson H; Kutteh L; Fox RM; Szekely EM; Tainer N; Lazarus HM
    J Clin Oncol; 2000 May; 18(9):1824-30. PubMed ID: 10784622
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A combination of low-dose cyclophosphamide and colony-stimulating factors is more cost-effective than granulocyte-colony-stimulating factors alone in mobilizing peripheral blood stem and progenitor cells.
    Meisenberg B; Brehm T; Schmeckel A; Miller W; McMillan R
    Transfusion; 1998 Feb; 38(2):209-15. PubMed ID: 9531956
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhancement of the anti-tumor activity of a peripheral blood progenitor cell graft by mobilization with interleukin 2 plus granulocyte colony-stimulating factor in patients with advanced breast cancer.
    Burns LJ; Weisdorf DJ; DeFor TE; Repka TL; Ogle KM; Hummer C; Miller JS
    Exp Hematol; 2000 Jan; 28(1):96-103. PubMed ID: 10658681
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Duration of filgrastim mobilization and apheresis yield of CD34+ progenitor cells and lymphoid subsets in normal donors for allogeneic transplantation.
    Anderlini P; Przepiorka D; Huh Y; Lauppe J; Miller P; Sundberg J; Seong D; Champlin R; Körbling M
    Br J Haematol; 1996 Jun; 93(4):940-2. PubMed ID: 8703830
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prolonged release and c-kit expression of haemopoietic precursor cells mobilized by stem cell factor and granulocyte colony stimulating factor.
    Roberts MM; Swart BW; Simmons PJ; Basser RL; Begley CG; To LB
    Br J Haematol; 1999 Mar; 104(4):778-84. PubMed ID: 10192440
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Filgrastim post-chemotherapy mobilizes more CD34+ cells with a different antigenic profile compared with use during steady-state hematopoiesis.
    Möhle R; Pförsich M; Fruehauf S; Witt B; Krämer A; Haas R
    Bone Marrow Transplant; 1994 Nov; 14(5):827-32. PubMed ID: 7534163
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pegfilgrastim compared with filgrastim for cytokine-alone mobilization of autologous haematopoietic stem and progenitor cells.
    Herbert KE; Gambell P; Link EK; Mouminoglu A; Wall DM; Harrison SJ; Ritchie DS; Seymour JF; Prince HM
    Bone Marrow Transplant; 2013 Mar; 48(3):351-6. PubMed ID: 22858510
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients.
    Shapiro CL; Ayash L; Webb IJ; Gelman R; Keating J; Williams L; Demetri G; Clark P; Elias A; Duggan D; Hayes D; Hurd D; Henderson IC
    J Clin Oncol; 1997 Feb; 15(2):674-83. PubMed ID: 9053493
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomised, blinded, placebo-controlled, dose escalation study of the tolerability and efficacy of filgrastim for haemopoietic stem cell mobilisation in patients with severe active rheumatoid arthritis.
    Snowden JA; Biggs JC; Milliken ST; Fuller A; Staniforth D; Passuello F; Renwick J; Brooks PM
    Bone Marrow Transplant; 1998 Dec; 22(11):1035-41. PubMed ID: 9877264
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors for successful mobilization of peripheral blood progenitor cells with ESHAP + G-CSF in patients with pretreated non-Hodgkin's lymphoma.
    Liu JH; Chen CC; Bai LY; Chao SC; Chang MS; Lin JS
    J Chin Med Assoc; 2008 Jun; 71(6):279-85. PubMed ID: 18567557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.